Clinical trials: Esophagogastric Junction Disorder
Stomach Neoplasms, Gastrointestinal Neoplasms
FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma
Patients with resectable adenocarcinoma of the stomach or the esophagogastric junction (II-III type by Siewert) without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Conditions
- Stomach Neoplasms, Gastrointestinal Neoplasms, Docetaxel, Oxaliplatin
- Trial name
- RusGCG-01 (NCT04393584)
- Testing
- Irinotecan, 5-FU, Leucovorin
- Where
- Russia
- Volunteers
- 538 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Gastric Cancer
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery.
- Trial name
- NCT01216644
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Germany
- Volunteers
- 716 people
- Sponsor
- Krankenhaus Nordwest
Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Advanced gastric cancer (AGC) and gastroesophageal junction (GEJ) adenocarcinoma remain associated with poor prognosis after failure of first-line systemic therapy.
- Conditions
- Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab
- Trial name
- NCT07692334
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Volunteers
- 28 people
- Sponsor
- West China Second University Hospital
Gastric Cancer, Lung Cancer
Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers
Tumors must be seen clearly on CT scan to be radiated completely and safely. Breathing causes tumors to move. If the tumor moves during breathing, it can look blurred on the CT scan. This makes it difficult to see on CT scan.
- Trial name
- NCT01213004
- Testing
- respiration correlated CT scan
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Esophageal Neoplasms, Gastro-esophageal Junction Cancer
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX.
- Trial name
- PROTECT (NCT02359968)
- Testing
- FOLFOX, CarboP-pacliT
- Where
- 10 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Oscar Lambret
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Obese Adults
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
This study will assess whether a single subcutaneous dose of tirzepatide 7.5 mg , compared with saline placebo, increases total esophageal acid exposure time during a 96-hour wireless pH recording beginning about 48 hours after…
- Trial name
- NCT07893457
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gastric Cancer
The Efficacy and Safety of Benmelstobart for GC/EGC
The goal of this clinical trial is to evaluate the major pathological response (MPR) rate of locally advanced gastric cancer / gastroesophageal junction cancer treated with bemosumab combined with antiangiogenic drugs and…
- Trial name
- EASOBFGE (NCT06603974)
- Testing
- surgery, Benmelstobart, tegafur
- Volunteers
- 48 people
- Sponsor
- Xijing Hospital
Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of Akt inhibitor MK2206 and lapatinib ditosylate when given together with trastuzumab in treating patients with locally advanced or metastatic human epidermal growth…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01705340
- Testing
- Akt inhibitor MK2206, trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT01498289
- Testing
- FOLFOX regimen, docetaxel, fluorouracil
- Where
- 508 sites in United States
- Volunteers
- 213 people
- Sponsor
- SWOG Cancer Research Network
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Stomach Neoplasms, Esophageal Neoplasms
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer.
- Trial name
- FOLFIRINOX (NCT01928290)
- Testing
- Irinotecan, Trastuzumab, Oxaliplatin
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington University School of Medicine
Squamous Cell Carcinoma, Adenocarcinoma
Chemoradiation and Panitumumab for Esophageal Cancer
A consistent finding in many studies in patients with operable esophageal and gastro-esophageal junction (GEJ) cancer is that response to preoperative therapy, particularly the absence of residual disease in the surgical…
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Esophageal Cancer, Gastro-esophageal Junction Cancer
- Trial name
- NCT01077999
- Testing
- Carboplatin, Paclitaxel, panitumumab
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer (EsC)
Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer
The objective of this observational study was to gain a deeper understanding of the epidemiology of the disease in Hungary through a broad analysis of patients with new-onset esophageal-oesophageal-stomach junction tumors, and to…
- Trial name
- NCT06713993
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University
Esophageal Adenocarcinoma, Esophageal Cancer
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Cancer, HER-2 Protein Overexpression, Gastroesophageal-junction Cancer
- Trial name
- NCT05480384
- Testing
- Nivolumab, Trastuzumab deruxtecan
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Breast Cancer, Gastric Cancer
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06341647
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Sponsor
- GC Cell Corporation
Stomach Cancer, Gastroesophageal Junction Cancer
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Previous studies provide a strong theoretical rationale for the conduct of a randomized study evaluating the efficacy and safety of ramucirumab in combination with FLOT in the perioperative treatment of resectable adenocarcinoma…
- Trial name
- RAMSES/FLOT7 (NCT02661971)
- Testing
- Docetaxel, Oxaliplatin, Calciumfolinat
- Where
- 2 sites in Germany, Italy
- Volunteers
- 180 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of INCA 0186 in Subjects With Advanced Solid Tumors
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when…
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Trial name
- NCT04989387
- Testing
- INCA00186, Retifanlimab, INCB106385
- Where
- 32 sites in United States, Austria and 4 more
- Volunteers
- 57 people
- Sponsor
- Incyte Corporation